Experience of Sorafenib as First-Line Treatment in Metastatic Renal Cell Carcinoma in a Tertiary Care Centre
AbstractBackground: Metastatic renal cell carcinoma is chemoresistant and radioresistant disease with poor survival historically, but outcome has improved in past decade after introduction of tyrosine kinase inhibitors like sunitinib and sorafenib. Sorafenib has not been tested in Indian patients with metastatic RCC till now. Material and Methods: This is a single arm, prospective, observational study done in unselected population of 60 patients with metastatic RCC treated with sorafenib as first- line therapy to assess efficacy and safety. Results: Twenty three out of 60 patients (38.33%) continued sorafenib by the end of the study. Overall response rates (ORR), stable disease (SD) and disease control rates (DCR) were 35%, 43.33% and 78.33%, respectively. Median progression- free survival (PFS) and overall survival (OS) were 6 and 8 months, respectively and associated with histopathology, Memorial Sloan Kettering Cancer Centre (MSKCC) risk groups, Heng risk groups and performance status. Best tolerated dose was 400 mg per day which was half of standard dose. Fatigue, diarrhea, rashes and hand foot syndrome were common side effects while hypertension was rare. Conclusion: Sorafenib, as first-line therapy, is an effective and safe treatment in Indian patients with metastatic RCC with poor tolerance to dose more than 400 mg per day. Side effects are mostly manageable.
Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55(2):74-108.
Schoffski P, Dumez H, Clement P, et al. Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: A review. Ann Oncol. 2006; 17(8):1185-96.
Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996; 335(12):865-75.
Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005; 353(23):2477-90.
Janzen NK, Kim HL, Flglin RA, et al. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am. 2003; 30(4):843-52.
Law TM, Motzer RJ, Mazumdar M, et al. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer. 1995; 76(5):824-32.
Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d′Immunothérapie. N Engl J Med. 1998; 338(18):1272-8.
Na X, Wu G, Ryan CK, et al. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. J Urol. 2003; 170 (2 Pt 1):588-92.
Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999; 399(6733):271-5.
Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum antitumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004; 64(19): 7099-109.
Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006; 24(16):2505-12.
Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356(2):125-34.
Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356(2): 115-24.
Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010; 28(6):1061-8.
Park SJ, Lee JL, Park I, et al. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma. Chemotherapy. 2012; 58(6):468-74.
Sheng X, Chi Z, Cui C, et al. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis. Ontarget. 2016; 7(19), 27044-54.
National Cancer Institute. Common Terminology Criteria's for Adverse Events Version 4.03; June 2010.
Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002; 20(1):289-96.
Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicentre study. J clin Oncol. 2009; 27(34):5794-9.
Escudier B, Szczylik C, Hutson TE, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009; 27(8):1280-9.
Jager D, Ma JH, Mardiak J, et al. Sorafenib treatment of advanced renal cell carcinoma patients in daily practice: The large international PREDICT study. Clin Genitourin Cancer. 2015; 13(2):156-64.e1.
Zhang H, Dong B, Lu JJ, et al. Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: Results from a multicentre study. BMC Cancer. 2009; 9:249.
Kim SH, Kim S, Nam BH, et al. Efficacy and safety of sorafenib therapy on metastatic renal cell carcinoma in Korean patients: Results from a retrospective multicentre study. PLoS One 2015; 10(8):e0136165.
Mills EJ, Rachlis B, O′Regan C, et al. Metastatic renal cell cancer treatments: An indirect comparison meta-analysis. BMC Cancer. 2009; 9:34.
Krishna VM, Noronha V, Prabhash K, et al. Sunitinib in metastatic renal cell carcimoma: A single-center experience. Indian J Cancer. 2013; 50(3):268-73.
Patel KB, Panchal HP, Karanwal AB, Parekh BB, Shah S, Prasad S. Sunitinib in metastatic renal cell carcinoma: Experience from single centre study, efficacy and safety. Indian J Cancer 2016; 53(1):118-122.